Guardian Pharmacy Services (GRDN) risk factors, FY2024 10-K

Risks Related to Our Business

1. 01Intense competition may erode our profit margins
2. 02Our prescription volumes may decline, and our operating results may be negatively impacted, if products are withdrawn from the market or if increased safety risk profiles of specific drugs result in utilization decreases
3. 03If we lose relationships with one or more pharmaceutical wholesalers or key manufacturers, or if such wholesalers or manufacturers refuse to extend our relationships on the same or similar terms, our business and financial results could be materially and adversely affected
4. 04Our operating results may suffer if we fail to maintain certain relationships and contracts with LTCFs we serve
5. 05The COVID-19 pandemic negatively impacted LTCFs and harmed our business. Another similar public health crisis, outbreak of infectious disease or national emergency could also have a negative impact on our business
6. 06If we fail to comply with Medicare and Medicaid regulations, we may be subjected to reduction in reimbursement, overpayment demands, or loss of eligibility to participate in these programs
7. 07Further modifications to the Medicare Part D program may reduce revenue and impose additional costs to the industry
8. 08Further consolidation of managed care organizations and other health plan payors, and changes in the terms of our agreements with these parties, may adversely affect our profits
9. 09We are highly dependent on our senior management team, our local pharmacy management teams and our pharmacy professionals and the loss of such persons could cause our business to suffer and materially adversely affect our operating results
10. 10Continued inflation and increases in labor costs may reduce our profitability
11. 11Government efforts to combat inflation, along with other interest rate pressures arising from an inflationary economic environment, could lead to us to incur even higher interest rates and financing costs and may reduce our profitability
12. 12Labor shortages could harm our ability to implement our growth strategy
13. 13If we or the LTCFs we serve fail to comply with state licensure requirements, we could be prevented from providing pharmacy services or be required to make significant changes to our operations
14. 14Complex and rapidly evolving laws and regulations could cause us to make significant changes to our operations or incur substantial costs or penalties
15. 15If we fail to comply with fraud and abuse laws, false claims provisions or other applicable laws, we may need to curtail operations, and could be subject to significant penalties
16. 16Federal and state privacy and security regulations may increase our cost of operations and expose us to civil and criminal sanctions, damages, and penalties
17. 17The increasing enforcement environment in the U.S. healthcare industry may negatively impact our business
18. 18Adverse results in material litigation matters or governmental inquiries could have a material adverse effect upon our business
19. 19Interruptions to our information systems may materially and adversely affect our operating results
20. 20Cybersecurity attacks or other data security incidents could disrupt our operations and expose us to regulatory fines or penalties, liability or reputational harm
21. 21We could be adversely affected by product liability, product recall, personal injury or other health and safety issues, and our insurance coverage may not be adequate to protect us against all potential risks and claims against us
22. 22Supply chain and other manufacturing disruptions or trade policies related to the pharmaceuticals we dispense could adversely impact our business
23. 23Acquisitions and strategic alliances that we have made or may make in the future could require significant resources, may be unsuccessful and could expose us to unforeseen liabilities
24. 24increases in our indebtedness
25. 25We may be exposed to potential liability and reputational harm if LTCF caregivers fail to properly administer the pharmaceuticals we dispense
26. 26We may be exposed to potential liability and reputational harm if we make errors in the course of providing medication reconciliation, duplicate therapy resolution, clinical issue resolution and related services
27. 27Our future success depends upon our ability to maintain and manage our growth. If we are unable to manage our growth effectively, we may incur unexpected expenses and be unable to meet the demands of our customers and other constituents
28. 28Our revenues and volume trends may be adversely affected by certain factors relevant to the markets in which we have pharmacies, including weather conditions and other natural disasters, some of which may not be covered by insurance

Risks Related to Ownership of Our Class A Common Stock

1. 29The Guardian Founders are able to exercise significant control over us, including through the election of all of our directors
2. 30We are a “controlled company” within the meaning of the corporate governance standards of NYSE. As a result, we qualify for exemptions from certain corporate governance standards and you do not have the same protections afforded to stockholders of companies that are subject to such requirements
3. 31Our future issuance of Class A common stock, Class B common stock, preferred stock or debt securities could dilute our common stockholders and adversely affect the market value of our Class A common stock
4. 32The market price of shares of our Class A common stock has experienced, and may in the future experience, substantial volatility
5. 33actual or expected operating performance, results of operations, financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our Class A common stock
6. 34The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain qualified board members
7. 35Future sales, or the perception of future sales of Class A common stock, by us or our existing stockholders in the public market could cause the market price for our common stock to decline
8. 36If we are unable to implement and maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our Class A common stock may decline
9. 37Our limited operating history as a publicly-traded company, and our inexperience could materially and adversely affect us and our stockholders
10. 38We do not intend to pay any cash dividends on our common stock in the foreseeable future
11. 39We are a holding company with no operations of its own and, accordingly, we depend on our subsidiaries for cash to fund our operations and expenses, including future dividend payments, if any
12. 40Our certificate of incorporation and bylaws and provisions of Delaware law may discourage or prevent certain strategic transactions, including a takeover of our company, even if such a transaction would be beneficial to our stockholders
13. 41These restrictions and provisions could keep us from pursuing relationships with strategic partners and from raising additional capital, which could impede our ability to expand our business and strengthen our competitive position